智飞生物(300122) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥11,395,682,504.71, representing a 2.00% increase compared to ¥11,172,773,125.45 in the same period last year[2] - Net profit attributable to shareholders decreased by 28.26% to ¥1,457,744,248.17 from ¥2,032,024,553.16 year-on-year[2] - The company's basic earnings per share fell by 28.07% to ¥0.6090 from ¥0.8467 in the same period last year[2] - Net profit for Q1 2024 was ¥1,457,744,248.17, a decrease of 28.2% from ¥2,032,024,553.16 in Q1 2023[18] - Basic and diluted earnings per share for Q1 2024 were both ¥0.6090, down from ¥0.8467 in Q1 2023[18] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥4,273,676,599.75, a decline of 310.92% compared to -¥1,040,028,831.23 in the previous year[9] - Total cash inflow from operating activities was ¥8,387,064,252.28, while total cash outflow was ¥12,660,740,852.03[20] - Cash flow from operating activities showed a net outflow of ¥4,273,676,599.75, compared to a net outflow of ¥1,040,028,831.23 in the previous year[20] - Cash and cash equivalents decreased by ¥3,368,736,087.79 in Q1 2024, compared to an increase of ¥176,160,972.80 in Q1 2023[21] - Cash and cash equivalents at the end of Q1 2024 stood at ¥2,970,554,147.12, up from ¥2,791,849,824.14 at the end of Q1 2023[21] - Cash inflow from financing activities was ¥4,097,486,152.00, significantly higher than ¥2,866,915,531.74 in Q1 2023[20] - Cash outflow for repaying debts was ¥2,629,363,041.00, compared to ¥1,350,079,178.00 in the previous year[20] - The company received ¥47,029,975.63 from other operating activities, an increase from ¥32,775,487.78 in Q1 2023[20] - The company reported a total cash outflow from investment activities of ¥236,232,912.39, compared to ¥270,977,272.24 in Q1 2023[20] Assets and Liabilities - The total assets increased by 6.64% to ¥53,568,800,848.87 from ¥50,232,190,314.35 year-on-year[3] - The company's total liabilities increased to CNY 20,905,005,959.51 from CNY 18,726,109,501.03, indicating higher leverage[15] - The total current assets amounted to CNY 45,731,274,065.90, an increase from CNY 42,514,016,731.06 at the beginning of the period[14] - Cash and cash equivalents decreased to CNY 2,971,776,140.82 from CNY 6,340,512,228.61[14] - Accounts receivable increased to CNY 30,029,039,075.81 from CNY 27,058,579,283.73, indicating a growth of approximately 7.3%[14] - Non-current assets include intangible assets valued at CNY 311,157,949.19, slightly down from CNY 317,684,334.76[14] Equity and Shareholder Information - The total equity attributable to shareholders increased by 3.67% to ¥32,663,794,889.36 from ¥31,506,080,813.32 year-on-year[3] - The company reported a total of 289,893,375 shares held by major shareholder Jiang Rensheng, representing a significant portion of the equity[12] - The top ten shareholders include institutional investors holding a combined total of 16,882,123 shares, accounting for 0.70% of total equity[12] - The company's total equity increased to CNY 32,663,794,889.36 from CNY 31,506,080,813.32, reflecting strong financial health[16] - Unappropriated profits grew to CNY 29,315,860,286.55 from CNY 27,858,116,038.38, showing retained earnings improvement[16] Operational Expenses - The company reported a significant increase in management expenses by 38.95% to ¥110,948,123.03, mainly due to higher fixed costs[8] - Operating costs for the same period were CNY 9,323,352,619.26, up from CNY 8,596,876,197.85, indicating a rise in expenses[17] - Research and development expenses for Q1 2024 were CNY 234,083,332.08, up from CNY 213,960,021.59, highlighting a focus on innovation[17] - The company has ongoing research and development efforts, with development expenditures recorded at CNY 1,039,736,765.37[14] Market Outlook and Strategy - The financial report indicates a stable outlook for the upcoming quarters, with a focus on maintaining liquidity and managing receivables effectively[12] - The company is exploring market expansion strategies, although specific details were not disclosed in the report[12]